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The latest research achievements in the field of stem cells led in 2016 to the publication of “Guidelines for Stem Cell Research and
Clinical Translation” by the International Society for Stem Cell Research (ISSCR). Updating the topics covered in previous
publications, the new recommendations offer interesting ethical and scientific insights. Under the common principles of
research integrity, protection of patient’s welfare, respect for the research subjects, transparency and social justice, the centrality
of good clinical practice, and informed consent in research and translational medicine is supported. The guidelines implement
the abovementioned publications, requiring rigor in all areas of research, promoting the validity of the scientific activity results
and emphasizing the need for an accurate and efficient public communication. This paper aims to analyze the aforementioned
guidelines in order to provide a valid interpretive tool for experts. In particular, a research activity focused on the bioethical,
scientific, and social implications of the new recommendations is carried out in order to provide food for thought. Finally,
as an emerging issue of potential impact of current guidelines, an overview on implications of compensation for egg
donation is offered.
1. Introduction
Stem cells are the starting point for the development of
human organism, representing the precursors of more than
200 cell types. Several studies on stem cells produced increas-
ingly important findings, with considerable implications on
the quality of human life, as in the case of the therapies for
intractable diseases, the assessment of efficacy and toxicity
of new drugs and transplants.
Responding to advances in research and translational
medicine, inMay 2016, the International Society for StemCell
Research (ISSCR) published an update of the existing guide-
lines [1, 2]. Expanding the thematic areas of previous publica-
tions, the new guidelines [3] offer interesting insights from an
ethical andscientificpointof view[4].Themost relevant topics
consist of research fairness, based on proven evidence studies
and transparency, and patient involvement through effective
and truthful communication. The guidelines are inspired by
the values already enshrined in key international documents
regarding scientific research and experimentation, such as
research rigor and integrity, supervision and transparency,
patient welfare, and social justice [5–7].
In the first part, the guidelines address the major innova-
tions in the field of research on human embryos and embry-
onic cells, such as genomic editing, focusing on the usefulness
of basic research to expand knowledge on the embryonic
development and stating that any attempt to modify the
genome of embryos for reproductive purposes is forbidden.
Moreover, the area of genome modification is extremely
important for the task force, as shown by the rising of
the ethical and scientific debate in various countries of
the world [8, 9].
For the first time, the ISSCR discusses the issue of human
induced pluripotent stem cells (hIPSC). The research on this
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type of cell is subjected to minor limitations because, despite
being very similar to embryonic cells, the IPSC are produced
from specialized adult cells (such as skin cells) and cannot
therefore be considered as embryonic.
The central points of the discussed guidelines are the
transparency and accessibility of data on preclinical and
clinical studies as well as the publication of the results in
referred scientific journals. According to this view, it is also
recommended the need for registration of all clinical trials
in progress or carried out in public databases, along with
the transparency of the results, in order to ensure a research
that is not burdened by fraud attempts. Coherently with
several authors, the transparency of the clinical data repre-
sents a driver of improved clinical outcomes as well as a
valuable tool to overcome the gap between professionals
and patients [10, 11].
About the involvement of patients in clinical studies and
the increasingly common commitment of the community of
patients in funding clinical trials, the guidelines stress the
need for these studies to follow the international rules on
clinical trials, including supervision by an independent
authority which guarantees rigor and scientific validity.
Another interesting aspect of the guidelines is repre-
sented by the theme of proper communication and
information about the results of scientific research on stem
cells. In fact, in setting up this research area as a center of
attraction for major funding, it is necessary to ensure the
appropriateness of information to prevent the spread of false
hopes and unsupported news by accredited and transparent
researches [12–15].
The new recommendations invite all the stakeholders
involved in the process of communication of scientific data
and especially the experts—researchers, clinicians, and
industry—to the utmost seriousness in the spreading of data
highlighting that scientists must endeavor to promote an
accurate, balanced, and effective information and must
ensure that the benefits, risks, and uncertainties of stem cell
science are not misrepresented. The guidelines support the
freedom of clinical research and the right of patients to hope.
The ISSCR guidelines, which are valid within the scientific
community, are obviously subject to the legislation and
regulations of individual nations, although they may provide
information on the interpretation of local laws and guidance
for research practices that are not covered by the legislation.
These principles are to be considered as basics in all
countries, and therefore, we must try to standardize the legal
systems of all the different states.
2. The Updated Guidelines
Although stem cell research and related implications have led
over the years to a considerable scientific and popular enthu-
siasm, the important development of regenerative medicine
has determined interesting challenges from an ethical and
scientific point of view.
The latest ISSCR guidelines about research in human
embryonic cell research and clinical application of stem cells
address several issues that are not included in previous
versions, with the aim to encompass government regulation,
institutional oversight, and communications enclosing basic
and translational research (Table 1).
The issues dealt within the latest recommendations are
discussed in the following paragraphs in order to highlight
the enormous usefulness of the guidelines in the field of
research and clinical trials.
3. Fundamental Ethical Principles
The variety and importance of ethical considerations regard-
ing research on stem cells is remarkable and, quite possibly,
without precedent. The entire path of research is character-
ized by risks, uncertainties, and problems that require a
careful assessment of the foreseeable damages in relation to
the expected benefits [16].
In the introductory section of the document, attention is
focused on the ethical principles that should guide human
stem cell research, clinical translation, and related research
activities. In particular, the authors perform a brief discus-
sion about the principles of research integrity, patient
welfare, respect for research subject, transparency, and social
justice (Table 2).
Table 1: Main issues from ISSCR 2016 “Guidelines for Stem Cell
Research and Clinical Translation”.
ISSCR—Guidelines for Stem Cell Research and Clinical
Translation
Fundamental ethical principles
Integrity of the research enterprise
Primacy of patient welfare
Respect for research subject
Transparency
Social justice
Laboratory-based human embryonic stem cell research, embryo
research, and related activities
Review processes
Procurement of biomaterials
Derivation, banking, and distribution of human pluripotent stem
cell lines
Mechanisms of enforcement
Clinical translation of stem cells
Cell processing and manufacture
Preclinical studies
Clinical research
Stem cell-based medical innovation
Clinical application
Communications
Public representation of science
Communication about clinical trials
Communication about clinical care
Standards in stem cell research
Standard development
Revising ethical guidelines
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4. Laboratory-Based Human Embryonic Stem
Cell Research, Embryo Research, and Related
Research Activities
At the core, the new recommendations maintain the notion
that the research requires a specialized supervisory process
conducted by qualified scientists, ethicists, and community
members. This process, defined embryo research oversight
(EMRO), aims to review, approve, and monitor all the
researches that involve preimplantation stages of human
development, human embryos, or embryo-derived cells or
entail the production of human gametes in vitro when such
gametes are tested by fertilization or used for the creation
of embryos. The guidelines exclude the recourse to a spe-
cialized EMRO in case of derivation of human pluripotent
stem cells from somatic cells via genetic or chemical
means of reprogramming (e.g., induced pluripotent stem
cells or IPSCs) as long as the research does not generate
human embryos or entail sensitive aspects of the research
use of human totipotent or pluripotent stem cells.
In the same section of the document, the authors identify
three categories of revision to be applied to guarantee that the
human embryo and research on embryonic stem cells are
proceeding with due consideration, to ensure the coherence
of research practices at the international level and specify
the nature of the scientific projects that should be subject to
review (Table 3).
Furthermore, on the basis of the EMRO process strictness
and with the aim of increasing the basic knowledge, the
ISSCR expresses its support to the research activities that
entail modifying the nuclear genomes of gametes, zygotes,
and/or preimplantation human embryos, however prohibit-
ing their application for the purpose of human reproduction
due to the limited notions that are currently available.
Due to the growing interest aroused by studies on
human-animal chimeras [17, 18], also shown by the recent
literature in the field of regenerative medicine [19–21], the
authors express a recommendation on the need for a special-
ized research oversight sustained by scientists and ethicists
with relevant expertise on the topic. This advice, besides sup-
porting a rigorous review process for the production of solid
scientific evidence, focuses on the ethical implications that
are determined by the involvement of animals in scientific
research [22–24], with specific reference to the application
of the animal welfare principles.
Regarding the procurement of biomaterials, the guidelines
update task force sustains a strict review process to be
undertaken before the procurement of gametes, embryos, or
somatic cells destined to scientific research [25]. A fundamen-
tal requirement for the acquisition of biomaterials is the
achievement of a valid informed consent. In this context, it
is recommended to verify the adequacy of information pro-
vided to the research participants [26]. Moreover, an explicit
informed consent for the research donation must be obtained
separately from the one proposed for the clinical treatment.
Since the informed consent document represents a single
aspect of the informed consent process, researchers must
enrich the dialogue with the providers of biomaterials in the
manner that is summarized below (Table 4).
In relation to the activities of derivation of new human
embryonic stem cell (hESC) lines, the ISSCR states that these
Table 2: Ethical bases of scientific research and translational
medicine.
Fundamental ethical principles underlying the new
recommendations
Integrity of the research enterprise
In order to generate high scientific credibility of evidence, a process
of supervision by qualified investigators that ensure the correctness
of information is desirable.
Primacy of patient welfare
Stem cell research and stem cell-based interventions must be
carried out according to the principles of the evidence-based
medicine, with the utmost respect for the welfare of research
subjects and/or patients.
Respect for research subjects
Consent procedures should prevent the overestimation of the
potential benefits of the proposed treatment. Subjects with
inadequate decision-making capacity must be protected from
nontherapeutic procedures that implicate greater than minor
increase over minimal risk.
The principle of respect for research subjects should be interpreted
more broadly to include other subjects such as tissue providers and
researchers who harbor conscientious objections regarding certain
aspects of the research.
Transparency
Researchers should properly inform the public and the scientific
community about the results of trials and preclinical research.
Social justice
The successes achieved in the field of clinical translation must be
equally and globally distributed with particular regard for
disadvantaged populations.
Table 3: Review categories recommended to improve the
supervision process.
Categories of review proposed for the oversight process
Category 1. Research that is permissible after review under existing
mandates and/or committees and is determined to be exempted
from the EMRO process
This category includes research with established human embryo-
derived stem cell lines and research involving the reprogramming
of human somatic cells to pluripotency.
Category 2. Forms of research that are permissible only after review
by an EMRO process, possibly in association with other supervisory
authorities
This category embodies activities based on the procurement and
use of IVF embryos and human gametes, genetic manipulation of
human embryos or gametes, derivation of new pluripotent cell
lines from human embryos, creation of human totipotent cells with
the potential to sustain embryonic or fetal development, and so
forth.
Category 3. Prohibited research activities
Research that cannot be pursued due to the lack of a scientific
rationale.
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should only be undertaken by qualified scientific personnel
and in the presence of a scientific rationale.
A further issue of considerable importance is represented
by incidental findings id est the discoveries concerning a
research participant or tissue donor that is not directly
related to the aims of a study but a carrier of potential impli-
cations on an individual’s health and reproductive life. In this
perspective, the debate on the right to be or not to be
informed is still extremely topical [27–31]. The recommen-
dations in this sense urge the development of policies
concerning the procedures for communication of incidental
findings to research subjects and promote the consultation
with the subject on the desire to receive and the ability to
select the eventual information.
In agreement with the views that are expressed in the
literature, the task force expresses categorically recommend-
ing the absolute traceability of the provenance of the stem cell
lines and the transparency of data [32, 33].
5. Clinical Translation of Stem Cells
The media attention on the field of stem cells together with
the numerous successes in animal studies has revealed the
need to take stock of the ethical issues related to the clinical
translation of knowledge about stem cells [34, 35].
In this regard, the authors have dedicated a whole section
to translational medicine focusing on cell processing and
manufacture, preclinical studies, clinical research, stem cell-
based medical innovation, and clinical application.
About cell processing and manufacture that are subject to
local government agencies’ regulation, the recommendations
highlight the need for an accurate, qualified, and indepen-
dent oversight review process, to guarantee the best integrity,
function, and safety of products. The involvement of donors
in the procurement of tissue activity should take place after
obtaining a valid informed consent [36] as well as after
screening for infectious diseases, risk factors, and, where
necessary, genetic diseases. Concerning the cellular deriva-
tives generated from tissue management, the authors
promote adherence to the standards of good manufacturing
practice (GMP) in accordance with local regulations. The
essentiality of an effective manufacture of products finds its
foundation in the enormous potential of cell therapies in
relation to the satisfaction of the patient’s needs, as well as
the desirability of promoting the transfer of the product in
clinical settings [37].
Another issue that is extensively discussed in the guide-
lines is represented by preclinical studies, due to their role
in the formation of evidence concerning the safety of prod-
ucts and the possible therapeutic efficacy. The evaluation on
the safety of cellular products must be made with particular
attention to the characterization of the cell lines, the potential
toxicity, the possible risk for tumorigenicity, the biodistribu-
tion, and the long-term effects of transplanted cells [38]. The
effectiveness of interventions based on the use of stem cells
must be tested on adequate animal models. In order to guar-
antee the correct interpretation of the data obtained during
the preclinical phase and form meaningful scientific
evidence, research actors must ensure the transparency of
information making preclinical studies completely accessible
whatever the outcomes.
The guidelines also devote a pathway to clinical research
promoting the protection of the welfare and rights of people
involved in the research, as well as ensuring the integrity of
the information resulting from scientific activities. In this
regard, it is recommended a constant, independent, and
expert oversight who is able to ensure the formation of solid
scientific evidence minimizing ethical issues. The conduction
of clinical research must be based on the assessment of the
evidence supporting the intervention, the analysis of risks
and benefits, the acquisition of a valid informed consent,
the achievement of a high level of competitiveness in com-
parison with existing therapies, and the safeguard of human
subjects’ privacy [39]. The protagonists of clinical trials have
to ensure that patients have a conscious and voluntary partic-
ipation through an approach aimed at improving the effec-
tiveness of information methods [40]. Early phase trials,
representing the first opportunity for the assessment of the
effects of innovative treatments in humans and being charac-
terized by high levels of uncertainty, imply a particular care
in avoiding the overestimation of benefits, ensuring a gradual
progression from low-risk to higher-risk experimental condi-
tions and maximizing the scientific value of the tests through
a perished and methodical activity. Late-phase trials should
provide results of high scientific credibility through the com-
parison between the new stem cell-based interventions and
the best currently available therapeutic approaches; in the
absence of treatments of proven efficacy, the comparison
should be carried out against placebo or sham comparators.
Given the persistence of stem cell treatments, a long-term
monitoring of the research subjects’ health conditions is
appropriate and recommendable. The characterization of
the effects of new treatments cannot be separated from the
autopsy which, if performed after the acquisition of a valid
informed consent, can provide data concerning cellular
implantation and functional consequences. Even at this
stage, the authors emphasize the importance of the publica-
tion of research results regardless of whether they are
positive, negative, or inconclusive, as well as the need to
report all possible adverse events [41, 42]. About the latter,
the implementation must not be limited to the number of
reports but rather to the characteristics of adverse reactions
such as gravity and predictability [43].
Table 4: Strategies to implement the informed consent process.
Recommendation to improve the informed consent process
The informed consent dialogue must be carried out in an accurate
and transparent manner, especially in the case of involvement of
research staff members.
Involvement in the research protocol should be discussed
extensively in an interactive and dynamic way.
A counseling service should be available to all donors prior to
procurement.
The consent procedures should be updated according to data from
research on informed consent as well as, where appropriate, the
studies on long-term risks associated with the collection.
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In the section on medical innovations, there is a warning
on the marketing of unproven interventions based on stem
cell. Specifically, the ISSCR condemns the administration of
not demonstrating interventions outside of the context of
clinical research or medical innovation compliant with the
guidelines and relevant laws, particularly when it is
performed as a business activity. The prohibitive approach
to the commercialization of unproven products is aimed at
the prevention of stem cell tourism, a phenomenon of great
social relevance based on the commercialization of treat-
ments that are not supported by scientific evidence [44, 45].
Regarding the clinical application, the appropriateness of
new products compared with national regulations and the
highest standards of evidence-based medicine assumes a
fundamental role [46, 47]. Since the clinical translation does
not end with the marketing authorization of the product, at
the end of high scientific credibility studies, surveillance on
safety and outcomes is recommended, as well as ensuring
their accessibility. The centrality of the report activity and
patient registries is discussed. Furthermore, on the off-label
use of stem cell-based interventions, the authors advise a
prudent behavior due to the uncertainties related to this type
of treatments.
6. Communications
A further issue considered in the discussed guidelines is
represented by the communication which, according to the
authors, is a crucial element because of the great deal of
attention received by the stem cell research from the scientific
and political world, as well as the public opinion [48].
On this line, the awareness of the fact that the population
coverage and scientific reporting are usually distant from the
ideal is emphasized. In fact, coherently with some authors,
there are some critical issues regarding the diffusion of over-
optimistic information and unrealistic data about the rate of
clinical translation by the media [49].
The recommendations are intended to promote a precise,
balanced, and understandable communication. In this per-
spective, according to several authors, the inconsistency of
data with the results must be avoided [50–53].
The promotion of adequate communication to the
patient both in timing and in methods is essential to improve
the quality and safety of care [54]. Information and commu-
nication technologies (ICTs) that are used in health care have
widely documented the benefits. ICTs include all digital
technology platforms capable of supporting the electronic
capture, storage, processing, and exchange of data with the
objective to promote health.
The virtuous process proposed involves several entities
from the scientific community up to political authorities,
through professionals, industry, and media communication.
7. Standards in Stem Cell Research
In the last section of the document, the ISSCR encourages
cooperation between the various research actors aimed at
the production of standards for stem cell research and trans-
lation, identifying some areas of interest and proposing
samples of informed consent documents to promote the
standardization process.
The confluence of standards concerning informed
consent and procurement of biomaterials, manufacturing
regulations, cell potency assays, minimally acceptable
changes during cell culture, methods of selection of recipients
for novel interventions, reporting of animal experiments,
design and reporting of trials, and principles for defining
information in datasets generates new opportunities for the
advancement of the research and knowledge concerning
stem cells.
Furthermore, based on new medical opportunities and
ethical challenges in the field of research on stem cells and
assisted reproduction techniques, the authors call for a com-
mon effort for the periodic review of the recommendations to
ensure that science and medical care advances responsibly
and ethically.
8. Compensation for Egg Donation: ISSCR
Point of View
In the section regarding procurement of biomaterials, the
Authors made a recommendation on the issue of payments
for individuals providing tissue for research. This purpose
arises from the need to focus on an ethical debate that has
been going on for many years. Ethics, law and policy on
payment for oocyte donation has received attention due to
the donation of eggs for embryonic stem cell (ESC)
research and nuclear transfer. The nature of the payment
to women donating oocyte for research has been the sub-
ject of international discussion due to the need to find a
fair solution for donors.
Despite the possibility of using other sources of supply,
the most realistic scenario for getting enough oocytes for
embryonic stem cell research and therapeutic needs in the
immediate future is constituted by living donors. At the state
of the art, the recourse to other techniques such as the use of
cadaveric or fetal ovaries requires a much greater amount of
knowledge than currently available. Researchers in the field
of stem cells have an obligation to carefully supervise this
scarce resource and have to make sure that the biomaterials
with which they work have been ethically obtained. In this
frame, compensation for research subjects represents a
commonly accepted concept, regulated by protocols and pro-
tective measures, except in cases where the reproductive
potential of women is involved [55, 56].
The guidelines very explicitly say that payment should be
to compensate, with the final purpose of offsetting nonfinan-
cial burdens for the subject. The concept of compensating
women for time, effort, and inconvenience spent on donating
oocytes presents considerable attractiveness in terms of jus-
tice and psychologic and physical involvement; in particular,
compensation for oocyte providers is ethically justified by the
philosophical aim of counter-balancing personal losses
endured by the research volunteer. The granting of compen-
sation is more justifiable considering the remarkable time,
effort, risk of complications, and discomfort sustained by
donors. In this regard, it should be remembered how much
the egg supply process is difficult, potentially risky, and
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characterized by a considerable amount of time.Women who
undergo these procedures must adhere to a stringent self-
administration of drugs for ovarian stimulation, with all the
risks associated with hyperstimulation and lack of knowledge
about the long-term effects of ovarian stimulation. Through-
out the process, which can also be very painful, women must
organize their daily lives by ensuring proper drug adminis-
tration and attend a series of hospital visits to monitor
clinical conditions and progress. Furthermore, such compen-
sation is consistent with the consolidated practice of paying
participants to biomedical research [57, 58].
On the other hand, as stated by Nuffield Council on Bio-
ethics Report on donation for medicine and research,
compensation has to be differentiated by incentive in
research ethics, considered as a recruitment tool to encourage
subjects to join a study and stay with it until the conclusion so
that sufficient data can be collected [59].
An important matter of interest is about the threat of
undue inducement and the possibility to enticing socioeco-
nomically disadvantaged women. It is not an ethical insignif-
icant consideration that the offer of compensation does not
in itself constitute an undue remuneration, exploitation, or
coercion of donors because, even in the absence of payment,
such issues tend to occur anyway [60]. As emphasized in the
guidelines, undue inducement has to be avoided. According
to the latest recommendations, protection of oocyte donors’
decisions from the risk of undue inducement should be based
on prior ethical review, informed consent, monitoring of
recruitment procedures, diligent practice, and careful evalua-
tion of the appropriateness of payment, as in other types of
donation. As an adjunct, in view of the nonbinding nature
of the guidelines, it would be desirable for local legislators
to make acceptable the compensation for egg donation as
for other types of research in the biomedical field.
9. Conclusions
The potential of interventions based on stem cells generates
ethical questions that need to be addressed before research
meets its objectives. The latest recommendations of ISSCR
appropriately respond to the advancement of knowledge in
the field of stem cell confronting emerging issues such as
the mitochondrial replacement for assisted reproduction.
Early studies on new biotechnologies are sometimes
supported by scientific debatable rationales and inadequate
study designs leading to overexcitement for new treatments
and unprejudiced commercialization of unproven interven-
tions. In this regard, the statement of ethical principles
underlying the scientific activity is an essential guide for
researchers, reviewers, and patients.
The most important feature of the latest ISSCR recom-
mendations is to lay the foundation for the protection of
the interests of patients, researchers, and industry in order
to ensure a productive collaboration in the field of stem cell
research and clinical translation.
According to the principles of good clinical practice [61],
the guidelines trace precise addresses in order to promote the
adoption of measures to maximize the clinical translation
and protect research participants.
Ultimately, it seems appropriate to emphasize the impor-
tance that the authors give to a central theme such as that of
patient information. In this perspective, the recommenda-
tions encourage proper information of research participants
and patients involved in the various phases of clinical trials.
As in other branches of medicine [62], a safe and accurate
information is critical to optimize patient participation and
prevent the spread of false hopes and news that are not
supported by evidence.
In conclusion, despite the achievement of notable suc-
cesses, the path is still arduous and research requires more
and more space as well as a targeted support to the pursuit
of increasingly ambitious objectives. Research frequently
encounters obstacles of ethical and moral nature that are a
counterweight to the impulses that lead science to the thresh-
old of human limitations, as in the case of using stem cells for
purposes of eugenics. In this landscape, the analyzed guide-
lines deal issues regarding stem cell research and clinical
translation, providing valid addresses to professionals and
their need of periodic update aimed at encouraging the bal-
ance between the ethical, scientific, political, and social issues.
What dowe learn from these ISSCRguidelines? It is neces-
sary tounderstand theneedsofprofessionals and support their
relationship with patients so to provide complete information
about treatments. Try to match technological advances with
the needs of patients and facilitate the decision-making
&#132;process in the selection of innovative therapies and
how treatment should be carried out with respect to informed
consent [46]. Not at least, besides taking into account the need
of constant progression of knowledge in a sensitive area such
as that of stem cells, the professionals should also comply with
mandatory regulations when available.
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